Rosuvastatin tablets recalled for manufacturing quality control deviations
Accord Healthcare is recalling rosuvastatin 40 mg tablets distributed in the US, Puerto Rico, and Canada due to manufacturing quality control deviations found during an FDA inspection. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for manufacturing practice deviations without any reported illnesses or injuries. Since no harm has been demonstrated and the hazard is theoretical, this qualifies as a precautionary recall with moderate severity.
Plain-English summary
Accord Healthcare, Inc. is recalling rosuvastatin calcium 40 mg tablets manufactured by Intas Pharmaceuticals Limited due to current good manufacturing practice (CGMP) deviations discovered during an FDA facility inspection.
The affected product was distributed in the United States, including Puerto Rico, and Canada. Approximately 102,360 bottles across multiple batch lots are included in this recall, with package sizes of 30-count, 90-count, and 1,000-count bottles. The affected batches have expiration dates ranging from December 2023 through August 2025.
No illnesses or injuries have been reported in connection with this recall. Patients currently taking this medication should consult their pharmacist or healthcare provider before making any changes to their treatment. Do not discontinue use without medical guidance.
The recalled product
- Product
- ROSUVASTATIN (ROSUVASTATIN)
- Brand
- ROSUVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug — Statin
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (19)
- Batches: a) P2100343
- Exp. Date 12/31/2023
- P2102371
- Exp. Date 3/31/2024
- b) P2101966
- Exp. Date 2/28/2024
- P2104545
- Exp. Date 6/30/2024
- P2204500
- Exp. Date 7/31/2025
- P2205415
- Exp. Date 8/31/2025
- c) P2101591
- Exp. Date 2/28/2023
- P2200062
- Exp. Date 12/31/2024
- P2204336
- P2204337
- P2205416
UPCs (3)
- 316729287104
- 316729287159
- 316729287173
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · ROSUVASTATIN
- HighRosuvastatin Tablets Recalled for Out-of-Specification Dissolution
FDA (Drugs) · 2026-01-14
- HighFDA Recalls Rosuvastatin Tablets Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighAccord Healthcare recalls Rosuvastatin tablets for manufacturing deviations
FDA (Drugs) · 2023-03-08
- ModerateRosuvastatin Tablets 5mg Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27